CurrentBlue Cross Blue Shield - South DakotaPolicy N/A

Urethral Drug-Coated Balloons for the Treatment of Urethral Stricture(s)

This policy governs coverage determinations for urethral drug-coated balloons (e.g., Optilume®) to treat obstructive urinary symptoms from anterior urethral strictures for Wellmark/Blue Cross Blue Shield - South Dakota members.

Policy Summary

PayerBlue Cross Blue Shield - South Dakota

PolicyUrethral Drug-Coated Balloons for the Treatment of Urethral Stricture(s)

Policy CodePolicy N/A

Change TypeAnnual review — no material changes

Effective DateApril 2024

Next Review DateN/A

Key ActionFollow payer-specific prior authorization processes when applicable and report CPT 52284 with appropriate documentation when billing for the Optilume procedure.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Dec 2021FDA PMA date

74.6% vs 26.8%Anatomical success (6 mo, ROBUST III)

83.2% vs 21.7%Freedom from repeat intervention (1 yr)

52284CPT code added

ROBUST I-IIIKey studies

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

80.8%Pooled recurrence-free rate

Coverage Determinations

inv-01: Investigational / Not covered as medically necessary

Covered when ALL of the following are met:

Investigational determination: Use of a urethral drug-coated balloon for treatment of obstructive urinary symptoms associated with urethral stricture(s) is considered investigational because evidence is insufficient to determine improvement in net health outcomes.

Includes Optilume®

inv-02: Coverage considerations aligned to trial populations and guideline recommendations

Consider DCB therapy for patients meeting STUDY/GUIDELINE‑aligned characteristics:

Patient selection

Stricture characteristics: Short strictures, generally <3 cm in length; trial eligibility included anterior strictures <12 Fr in diameter and <3 cm in length.<3 cm
ROBUST III eligibility and guideline emphasis on short/bulbar strictures.
Prior treatments: Recurrent strictures after at least two prior endoscopic treatments (dilation or DVIU) as specified in guideline recommendations and the randomized trial enrollment criteria.>=2 prior endoscopic treatments
EAU/AUA guidance and ROBUST III trial population.

Comparators and positioning: DCB compared to uncoated balloon dilation and DVIU; pivotal RCTs did not compare DCB to urethroplasty. Urethroplasty remains an alternative, and guidelines suggest offering DCB when urethroplasty is not an option.

Reflects comparator context from trials and guideline positioning.

Optilume® is contraindicated in individuals with known hypersensitivity to paclitaxel or structurally related compounds. The device is also contraindicated in patients with certain urologic implants (for example, penile implants or artificial urinary sphincters) where placement or interaction with the device could pose risk.

The clinical evidence primarily enrolled patients with anterior (typically bulbar) short strictures, and most trial subjects had bulbar strictures; therefore applicability to non-bulbar locations or longer strictures (>3 cm) is uncertain. The randomized controlled trial(s) compared the drug-coated balloon to endoscopic management (dilation or DVIU) and did not directly compare DCBs to urethroplasty, limiting conclusions about comparative effectiveness for longer or more complex strictures.

The policy documentation does not list additional explicit clinical exclusions beyond device-specific contraindications (e.g., paclitaxel hypersensitivity and presence of certain urologic implants).

Although systematic reviews and an RCT (ROBUST III) report reduced recurrence and improved urinary flow and symptom scores with Optilume® versus endoscopic management, the overall body of evidence has limitations—short follow-up in many studies, limited numbers of randomized comparisons, and lack of direct comparison with urethroplasty. Because of these evidence gaps, the use of urethral drug-coated balloons cannot be concluded to improve net health outcomes.

Given the available data, drug-coated balloons are not supported for unrestricted use across all anterior urethral strictures. Evidence is strongest for short bulbar strictures as studied in trials; therefore DCBs are not considered a universal standard treatment for all anterior strictures and should be considered investigational outside the studied populations and contexts.

The policy cites key studies and guideline assessments (including the ROBUST trials and recent guideline amendments) that report favorable short-term outcomes with DCBs but note limitations such as limited generalizability, higher hematuria in the treatment arm, and lack of long-term comparative data. These references inform the investigational determination without restating a specific ‘‘Not Medically Necessary’’ phrasing in each citation.

Coding and Billing

Covered CPT CodesCPTCovered

52284

Cystourethroscopy, with mechanical urethral dilation and urethral therapeutic drug delivery by drug-coated balloon catheter for urethral stricture or stenosis, male, including fluoroscopy, when performed.

HCPCSHCPCS

No code(s)

HCPCS: No specific HCPCS code listed

Service Typemixed

Surgery

Type of Service

Place of Servicemixed

Outpatient

Place of Service

Stricture length (per FDA indication)

FDA PMA indication (length)> 3 cm

Anatomical siteAnterior urethral stricture

Patient populationAdult XY individuals

Provider Requirements and Operational Notes

Prior Authorization

Prior approval is not applicable for this policy; however, the urethral drug-coated balloon (e.g., Optilume®) is designated investigational and may be denied as the evidence is insufficient to determine improvement in net health outcomes.

Investigational designation — potential for denial.

Prior Authorization

Prior Authorization Recommended for Recurrent Bulbar Strictures

For recurrent bulbar urethral strictures (<3 cm) the 2023 AUA guideline amendment states surgeons may offer dilation or DVIU combined with drug-coated balloons (Conditional Recommendation; Grade B). When used in this guideline-aligned scenario, prior authorization is recommended to ensure appropriate patient selection and documentation of prior endoscopic treatments.

AUA 2023 guideline: recurrent bulbar strictures <3 cm — DCB may be offered.
Recommend prior authorization when DCB is used after prior endoscopic treatments (e.g., ≥1 prior dilation/DVIU).

Clinical Background

Urethral strictures are focal narrowing of the urethral lumen that often produce lower urinary tract symptoms such as a decreased urinary stream, hesitancy, incomplete bladder emptying, and recurrent urinary tract infections. Etiologies include idiopathic and iatrogenic causes. Management depends on stricture location and length; short bulbar strictures are commonly treated with dilation, DVIU, or urethroplasty, but recurrence rates are high and newer adjunctive options such as paclitaxel-coated urethral balloons have been evaluated to reduce recurrence.

Definitions and Device Status

Urethral drug-coated balloon — definition

DefinitionA urethral balloon catheter coated with an antiproliferative agent (e.g., paclitaxel) that dilates the urethral lumen and transfers drug to the stricture site to relieve obstructive urinary symptoms.

PurposeMinimally invasive alternative to endoscopic management or urethroplasty for anterior urethral strictures.

Typical useDelivered during cystourethroscopy with balloon dilation and therapeutic drug transfer.

Optilume® / device regulatory status — indication and FDA status

DeviceOptilume® Urethral Drug Coated Balloon (Urotronic, Inc.)

Regulatory statusFDA premarket approval (PMA P210020) — received December 2021

Policy Revision History

March 2025annual_reviewLatest

Policy renewed following annual review.

March 2024policy_creation

New medical policy created for urethral drug-coated balloons (Optilume®).

Policy Summary

PayerBlue Cross Blue Shield - South Dakota

PolicyUrethral Drug-Coated Balloons for the Treatment of Urethral Stricture(s)

Policy CodePolicy N/A

Change TypeAnnual review — no material changes

Effective DateApril 2024

Next Review DateN/A

Key ActionFollow payer-specific prior authorization processes when applicable and report CPT 52284 with appropriate documentation when billing for the Optilume procedure.

SourceLink

On This Page

Billing Rule

Prior Authorization and Billing

When billing, report the appropriate CPT code (52284) and outpatient place/type of service. Prior authorization is not required per policy header, but accurate coding and place of service are necessary to avoid coding-related denials.

Report CPT 52284: Cystourethroscopy with mechanical urethral dilation and therapeutic drug delivery by drug-coated balloon.
Place of Service: Outpatient (surgery).
Ensure accurate procedure details on the claim to reduce denial risk.

Denial Risk

Evidence Insufficiency and Coverage Stance

The body of evidence includes one RCT showing reduced stricture recurrence and improved flow and symptom scores versus endoscopic management, but limitations (primarily short follow-up beyond 2 years, predominance of bulbar strictures, and absence of comparison with urethroplasty) leave uncertainty about long-term net health outcome benefit. Evidence is therefore insufficient to support routine coverage.

RCT (ROBUST III) showed anatomical success at 6 months (74.6% DCB vs 26.8% control) and higher freedom from repeat intervention at 1 year.
Limitations: limited long-term data, generalizability mostly to bulbar strictures, no direct comparison to urethroplasty.

Note

Existing Therapy Context

Standard initial treatments for short (<2 cm) bulbar strictures include urethral dilation, DVIU, or urethroplasty. Drug-coated balloons are positioned as an adjunctive treatment following prior endoscopic therapies to attempt to reduce high recurrence rates.

Initial non‑urgent treatment for short bulbar strictures: dilation, DVIU, or urethroplasty.
DCB (Optilume®) considered an adjunctive option to address recurrence after endoscopic treatments.

Note

Comparators and Guideline Positioning

Comparators include uncoated balloon dilation, DVIU (endoscopic management), and urethroplasty. Clinical trials generally used uncoated balloon dilation or other endoscopic management as the control; DCB has not been compared directly to urethroplasty in randomized trials.

Comparator treatments: uncoated balloon dilation, endoscopic management (DVIU), urethroplasty.
RCT controls were standard endoscopic treatments (serial dilation, uncoated balloon, DVIU).

Indication per FDATreatment of obstructive urinary symptoms associated with anterior urethral stricture in adult XY individuals for urethral stricture > 3 cm in length.

Drug-coated balloon (DCB) — definition and mechanism

DefinitionA balloon catheter coated with an antiproliferative drug (commonly paclitaxel) used to dilate anterior urethral strictures and locally deliver the drug to the stricture site.

MechanismMechanical dilation of the stricture combined with transfer of antiproliferative agent from the balloon surface to reduce restenosis.

Clinical roleOffered as a minimally invasive option compared with uncoated balloon dilation, DVIU, or urethroplasty in selected patients.

Anatomical success — definition used in trials

Trial definitionAnatomical success = urethral diameter ≥14 French determined by cystoscopy or calibration at 6 months post-procedure (as used in ROBUST III).

Primary endpoint timingAssessed at 6 months after procedure in ROBUST III trial.

Method of assessmentUrethral cystoscopy or calibration to measure lumen diameter (≥14 Fr threshold).

Optilume — key device identifier

Proprietary nameOptilume®

ManufacturerUrotronic, Inc.

Product code / PMAPMA P210020 (product code: QRH) — FDA approval December 2021